Tyrosine Kinase 2 Inhibitor class drugs

1 result

Sotyktu (deucravacitinib)

(deucravacitinib)
E.R. Squibb & Sons, L.L.C.
Usage: SOTYKTU™ is indicated for the treatment of moderate-to-severe plaque psoriasis in adults suitable for systemic therapy or phototherapy. It is not recommended for use with other potent immunosuppressants.